Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types

This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other insurance for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.

Detalles Bibliográficos
Autores principales: Tummalapalli, Sri Lekha, Montealegre, Julio Lamprea, Warnock, Neil, Green, Michael, Ibrahim, Said A., Estrella, Michelle M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796944/
https://www.ncbi.nlm.nih.gov/pubmed/35977296
http://dx.doi.org/10.1001/jamahealthforum.2021.4205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796944/
https://www.ncbi.nlm.nih.gov/pubmed/35977296
http://dx.doi.org/10.1001/jamahealthforum.2021.4205

Ejemplares similares